The discovery of effective coronovirus treatment is a major step forward with some help from the National Institutes of Health: NIH has launched a phase 3 clinical trial that can tell which experimental antibody treatments for COVID-19 are the most effective Huh.
Multiple treatment candidates will be administered to hospitalize COVID-19 patients at participating institutions across the US but will be tested first with LY-CoV555 in the study. Eli Lilly (NYSE: LLY). It is derived from an antibody originally identified in a patient who has recovered from a severe case of COVID-19.
In addition to a placebo, the ACTIV-3 trial will compare how LY-CoV555 stacks up against multiple injection treatments from other pharmaceutical companies. The agency has not mentioned the next candidate in the list for the study, but we can reasonably expect Regeneron (NASDAQ: REGN) To field their dual antibody cocktail, REGN-COV2.
Regeneron has already begun a phase 3 trial with REGN-COV2 in partnership with NIH to find out that it can protect people who had close contact with COVID-19 patients. The Regeneron candidate is also in the final stages of an adaptive trial among hospitalized patients designed to support its final FDA approval.
This is not the first phase 3 trial of LY-CoV555 that Lily has initiated in partnership with NIH. On Monday, the company launched a study, called Blaze-2, which will enroll 2,400 nursing home residents and the employees who care for them. NIH will also begin a Phase 2 trial of LY-CoV555, administered to approximately 220 patients with mild to moderate cases of COVID-19; If the study phase 2 is successful, a 2,000-patient phase 3 trial can be upgraded.